News

CA4P is a type of drug called a vascular disrupting agent (VDA) as it selectively blocks blood vessels in tumors causing widespread tumor death. The study showed that

Jones has been working with Acura Pharma since April 2008 as the senior vice president and chief operating officer. Jones succeeds Andy Reddick, who passed away on 28

Keryx‘s operating loss was $6.48m, compared to $4.1m for the same period in 2010. Other research and development expenses, for the first quarter ended 31 March 2011, increased

As per the terms of the agreement, Prometheus is responsible to pay a sum of $19m upfront payment and development fees plus milestone payments and royalties on Rencarex

For the first quarter of 2011, the company has reported a net profit of EUR18.8m, or EUR0.81 per diluted share, compared to EUR3.2m, or EUR0.14 per diluted share,

Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the marine tunicate, Ecteinascidia turbinata. The company’s decision was based on the US Food and Drug

Strides‘ oncology facility was established in 2009 and it manufactures injectables, oral products (tablets and softgels) in the oncology domain. The approval will allow the company to widen

Fusilev is a folate analog, which is approved as a ready-to-use (Fusilev injection) solution in 175mg and 250mg vials, and as freeze-dried powder (Fusilev for injection) in 50mg

The new application manages the entire sales talent lifecycle from onboarding, to incentives and rewards, to coaching and performance optimization, while offering visibility into operations and financial performance.